Pembrolizumab,Lenvatinib,Regorafenib,trifluridine,Tipiracil
Merck,Eisai,Bayer,Taiho pharma,Pfizer
['crc,(-ccrcc),(-tbcrc049),(-mccrcc),(-mbcrc)', 'trifluridine,tipiracil', 'ts,perio,1', 'ts,perio,01', 'trifluridine', 'regorafenib', 'pembro', 'lenva', 'ts,perio,i']
lenvatinib plus pembrolizumab vs regorafenib or tas for previously treated mcrc: phase 3 leap-017 study at #wcgic2023 mos: 9.8 vs 9.3 mo there is some activity, but io in mss crc remains a challenge... 
Physician-scientist, focused on translational research in hepatobiliary cancer and precision oncology